Please login to the form below

Not currently logged in
Email:
Password:

multiple myeloma

This page shows the latest multiple myeloma news and features for those working in and with pharma, biotech and healthcare.

Takeda’s subcutaneous Entyvio formulation faces FDA rejection

Takeda’s subcutaneous Entyvio formulation faces FDA rejection

The anti-integrin antibody Entyvio (vedolizumab) is an important growth products for Takeda as it faces loss of patent protection in the US for its blockbuster multiple myeloma drug Velcade (bortezomib).

Latest news

More from news
Approximately 56 fully matching, plus 226 partially matching documents found.

Latest Intelligence

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    The antibody specialist company is riding high on the success of Darzalex, the multiple myeloma therapy which it has co-developed and co-marketed with J&J, and which is set

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    Its most important pipeline candidate, however, is the multiple myeloma targeting CAR-T therapy bb2121, being co-developed with Celgene.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    4. Mayzent – a latest addition to competitive MS market. Novartis’ Mayzent (siponimod) is expected to be launched in the US in Q1 for multiple sclerosis, with an EU launch to follow ... EvaluatePharma has predicted it could become a nearly $2.5bn

  • Deal Watch October 2018

    treatment of multiple myeloma and other conditions. Joint development. agreement. $665m. ... Who’s the winner? We won’t know for many years. Multiple deals from Gilead too.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    ASCO last year, and a larger, 1, 000-patient study across multiple cancers is due to report in 2020. ... The CAR-Ts have transformed the treatment of childhood ALL – an otherwise incurable blood cancer – and have been shown to work in hard-to-treat

More from intelligence
Approximately 0 fully matching, plus 24 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics